Skip to main content

Advertisement

SpringerLink
Log in

Cytogenetics and molecular genetics

Familial myeloid malignancies with germline TET2 mutation

  • Letter
  • Published:
Leukemia Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1: Germline TET2 mutation with myeloid malignancies.

References

  1. Delhommeau F, Dupont S, Valle VD, James C, Trannoy S, Masse A, et al. Mutation in TET2 in myeloid cancers. N Engl J Med. 2009;360:2289–301.

    Article  Google Scholar 

  2. Solary E, Bernard OA, Tefferi A, Fuks F, Vainchenker W. The ten-eleven translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases. Leukemia. 2014;28:485–96.

    Article  CAS  Google Scholar 

  3. Kosmider O, Gelsi-Boyer V, Ciudad M, Racoeur C, Jooste V, Vey N, et al. TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. Haematologica. 2009;94:1676–81.

    Article  CAS  Google Scholar 

  4. Kosmider O, Gelsi-Boyer V, Cheok M, Grabar S, Della-Valle V, Picard F, et al. TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Blood. 2009;114:3285–91.

    Article  CAS  Google Scholar 

  5. Nibourel O, Kosmider O, Cheok M, Boissel N, Renneville A, Philippe N, et al. Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission. Blood. 2010;116:1132–5.

    Article  CAS  Google Scholar 

  6. Tefferi A, Pardanani A, Lim K-H, Abdel-Wahab O, Lasho TL, Patel J, et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia. 2009;23:905–11.

    Article  CAS  Google Scholar 

  7. Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371:2488–98.

    Article  Google Scholar 

  8. Renaud L, Nibourel O, Marceau‐Renaut A, Gruson B, Cambier N, Lionne‐Huyghe P, et al. Comprehensive molecular landscape in patients older than 80 years old diagnosed with acute myeloid leukemia: a study of the French Hauts-de-France AML observatory. Am J Hematol. 2019;94:E24–7.

    Article  Google Scholar 

  9. Kaasinen E, Kuismin O, Rajamäki K, Ristolainen H, Aavikko M, Kondelin J, et al. Impact of constitutional TET2 haploinsufficiency on molecular and clinical phenotype in humans. Nat Commun. 2019;10:1252.

    Article  Google Scholar 

  10. Schaub FX, Looser R, Li S, Hao-Shen H, Lehmann T, Tichelli A, et al. Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms. Blood. 2010;115:2003–7.

    Article  CAS  Google Scholar 

  11. Selimoglu-Buet D, Wagner-Ballon O, Saada V, Bardet V, Itzykson R, Bencheikh L, et al. Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia. Blood. 2015;125:3618–26.

  12. Lorsbach RB, Moore J, Mathew S, Raimondi SC, Mukatira ST, Downing JR. TET1, a member of a novel protein family, is fused to MLL in acute myeloid leukemia containing the t(10;11)(q22;q23). Leukemia. 2003;17:637–41.

    Article  CAS  Google Scholar 

  13. Pozdeyev N, Gay LM, Sokol ES, Hartmaier R, Deaver KE, Davis S, et al. Genetic analysis of 779 advanced differentiated and anaplastic thyroid cancers. Clin Cancer Res. 2018;24:3059–68.

    Article  CAS  Google Scholar 

  14. Duployez N, Lejeune S, Renneville A, Preudhomme C. Myelodysplastic syndromes and acute leukemia with genetic predispositions: a new challenge for hematologists. Expert Rev Hematol. 2016;9:1189–202.

    Article  CAS  Google Scholar 

  15. Jongen-Lavrencic M, Grob T, Hanekamp D, Kavelaars FG, al Hinai A, Zeilemaker A, et al. Molecular minimal residual disease in acute myeloid leukemia. N Engl J Med. 2018;378:1189–99.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank the family members who participated in this study. We thank Christophe Roumier (Tumor Bank, certification NF 96900-2014/65453-1, Centre Hospitalier Universitaire de Lille) for handling, conditioning, and storing patient samples.

Author information

Authors and Affiliations

  1. CHU Lille, Laboratory of Hematology, F-59000, Lille, France

    Nicolas Duployez, Laurène Fenwarth, Alice Marceau-Renaut, Thomas Boyer, Elise Fournier, Olivier Nibourel & Claude Preudhomme

  2. INSERM, UMR-S 1172, F-59000, Lille, France

    Nicolas Duployez, Laurène Fenwarth, Alice Marceau-Renaut, Thomas Boyer, Olivier Nibourel, Catherine Roche-Lestienne, Guillemette Huet, Céline Berthon, Bruno Quesnel & Claude Preudhomme

  3. CHU Lille, Department of Hematology, F-59000, Lille, France

    Laure Goursaud, David Beauvais, Céline Berthon, Nathalie Cambier & Bruno Quesnel

  4. CH Lens, Department of Hematology, F-62307, Lens, France

    Claire Bories

  5. CH Dunkerque, Laboratory of Hematology, F-59385, Dunkerque, France

    Elise Fournier

  6. CHU Lille, Department of Medical Genetics, F-59000, Lille, France

    Catherine Roche-Lestienne

  7. CHU Lille, Cell Culture Department, F-59000, Lille, France

    Guillemette Huet

  8. CH Valenciennes, Department of Hematology, F-59322, Valenciennes, France

    Nathalie Cambier

Authors
  1. Nicolas Duployez
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Laure Goursaud
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Laurène Fenwarth
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Claire Bories
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Alice Marceau-Renaut
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Thomas Boyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Elise Fournier
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Olivier Nibourel
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Catherine Roche-Lestienne
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Guillemette Huet
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. David Beauvais
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Céline Berthon
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Nathalie Cambier
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Bruno Quesnel
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Claude Preudhomme
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

ND, LF, AMR, and ON performed molecular studies and analyzed mutational data. TB and EF performed morphological examinations and flow cytometry. CRL performed genetic analysis. GH performed fibroblast culture. LG, CB, DB, CB, NC, and BQ provided samples and clinical data. ND and CP wrote the manuscript, which was approved by all the authors.

Corresponding author

Correspondence to Nicolas Duployez.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Duployez, N., Goursaud, L., Fenwarth, L. et al. Familial myeloid malignancies with germline TET2 mutation. Leukemia 34, 1450–1453 (2020). https://doi.org/10.1038/s41375-019-0675-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41375-019-0675-6

  • Springer Nature Limited

This article is cited by

Search

Navigation